Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice. Ahead ...
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, ...
The scope covers prescription drugs and drug-led, drug-device combination products where the Center for Drug Evaluation and ...
Germany is the European Union’s (EU) largest pharmaceutical market by revenue and has the highest medical biotechnology ...
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human ...
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors ...
AstraZeneca and insitro announced on Oct. 15, 2026, a strategic drug discovery collaboration and licensing agreement that ...
Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
As GLP-1 therapies evolve from single-agonist peptides toward dual and triple agonists, formulation and CMC teams face a more ...
PharmTech covered one of the industry’s biggest events this week, as CPHI Milan was in full force with experts arguing that ...
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results